Abstract:ROR1 and Aurora kinase were overexpressed in various cancers and essential for cell proliferation, survive and metastasis. Pharmaceutical inhibition of ROR1 and Aurora kinase abrogated the activation of downstream signaling and induced cancer cell apoptosis. Hence, ROR1 and Aurora kinase considered as attractive therapeutic targets for the development of anticancer drugs. In the present work, three series of novel 6-(imidazo[1,2-a] pyridin-6-yl)-quinazolin-4(3H)-one derivatives were designed and synthesized via bioisosterism and scaffold-hopping strategies guided by FLF-13, an Aurora kinase inhibitor we discovered earlier. Most of compounds in series 2 and series 3 showed submicromolar to nanomolar inhibitory activity against multiple cancer cell lines. More importantly, compounds 12d and 12f in series 3 showed nanomolar inhibitory activity against all test cancer cells. The most promising compound 12d exhibited potent inhibitory activity against Aurora A and Aurora B with IC<sub>50</sub> values of 84.41 nM and 14.09 nM, respectively. Accordingly, compounds 12d induced G2/M phase cell cycle arrest at 24 h and polyploidy at 48 h. It's worth noting that 12d also displayed inhibitory activity against ROR1 and induce cell apoptosis. Furthermore, 12d could significantly inhibit the tumor growth in SH-SY5Y xenograft model with tumor growth inhibitory rate (IR) up to 46.31 % at 10 mg/kg and 52.66 % at 20 mg/kg. Overall, our data suggested that 12d might serve as a promising candidate for the development of therapeutic agents for cancers with aberrant expression of ROR1 and Aurora kinases by simultaneously targeting ROR1 and Aurora kinase.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Identification of 3,5,6-Substituted Indolin-2-one’s Inhibitors of Aurora B by Development of a Luminescent Kinase Assay

Discovery of Novel 2,4-Disubstituted Pyrimidines As Aurora Kinase Inhibitors.

Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.

Synthesis and Biological Evaluation of 2,4-Diaminopyrimidines As Selective Aurora A Kinase Inhibitors.

Discovery of Inhibitors of Aurora/PLK Targets As Anticancer Agents.

Pharmacophore Modelling and Virtual Screening for Identification of New Aurora-A Kinase Inhibitors

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1

Design and Synthesis of (E)-3-benzylideneindolin-2-one Derivatives As Potential Allosteric Inhibitors of Aurora A Kinase

3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors

Discovery of 4-Aminoquinazoline—urea Derivatives As Aurora Kinase Inhibitors with Antiproliferative Activity

Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors

Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen

Design, Synthesis and Bioevaluation of Dihydropyrazolo[3,4-B]pyridine and Benzo[4,5]imidazo[1,2-A]pyrimidine Compounds As Dual KSP and Aurora-A Kinase Inhibitors for Anti-Cancer Agents.

Identification of an Aurora Kinase Inhibitor Specific for the Aurora B Isoform

Design, Synthesis, Biological Evaluation of 6-(2-amino-1h-benzo[d]imidazole-6-yl)quinazolin-4(3h)-one Derivatives As Novel Anticancer Agents with Aurora Kinase Inhibition.

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.

Synthesis and Biological Evaluation of Aurora Kinases Inhibitors Based on N-trisubstituted Pyrimidine Scaffold

Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine Derivatives As New Multi-Targeted Inhibitors of Aurora A/B and KDR.

Combined 3d-Qsar Modeling And Molecular Docking Studies On Pyrrole-Indolin-2-Ones As Aurora A Kinase Inhibitors